Press releases

Worldwide Business Research and Pharmalicensing jointly awarded Endo Pharmaceuticals and Vernalis the BioBusiness Network Innovative Partnership 2004 award at BioBusiness Network 2004 in Geneva, Switzerland More

SVT-40776, the selective M3 muscarinic antagonist under development by SALVAT for the treatment of urinary incontinence, is now entering Phase II clinical studies. More

We offer complete global expert pharmacovigilance support to small and midsize companies, and project specific pharmacovigilance assistance to big pharmaceutical companies. More

Drug desensitization is an overlooked side effect of many drugs. Desensitization often contributes to a person's inability to tolerate many common medications including those for the heart, pain or asthma. More

Worldwide Business Research and Pharmalicensing jointly awarded Endo Pharmaceuticals and Vernalis the BioBusiness Network Innovative Partnership 2004 award at BioBusiness Network 2004 in Geneva, Switzerland More

Roche Protein Expression Group offers Protein Identification Services More